Literature DB >> 11474474

Cardiovascular risk factors in men: The role of gonadal steroids and sex hormone-binding globulin.

J Gyllenborg1, S L Rasmussen, K Borch-Johnsen, B L Heitmann, N E Skakkebaek, A Juul.   

Abstract

Males have higher risk of cardiovascular disease (CVD) than premenopausal females. Gonadal steroids are probably involved in the gender difference in CVD, but previous results have been conflicting. We investigated the associations between CVD risk factors and sex hormones in a cross-sectional designed study of 508 healthy males, aged 41 to 72 years. We determined total testosterone (T), sex hormone-binding globulin (SHBG), free androgen index (FAI), and estradiol (E2) and studied their relationship to body fat mass (BF), blood pressure (BP), aortic compliance, left ventricular mass (LVM), and plasma lipids (total cholesterol, high-density lipoprotein [HDL], low-density lipoprotein [LDL], very--low-density lipoprotein [VLDL], and triglycerides). In quartile analyses after adjustment for confounders (age, body mass index [BMI], alcohol consumption, and smoking), SHBG and E2 were positively associated with HDL, while FAI was negatively associated with HDL. T and SHBG were negatively associated with VLDL and triglycerides, while FAI was positively associated with VLDL and triglycerides. T and SHBG were negatively associated with BMI and BF, while FAI and E2 were positively associated with BMI and BF. E2 was negatively associated with LVM. No hormone varied with total cholesterol, LDL, BP, and aortic compliance in the adjusted analyses. In multiple regression analyses, SHBG was the main predictive variable of HDL, VLDL, and triglycerides explaining 12%, 17%, and 17% of the variation, respectively. No other hormones were selected as predictive variables for VLDL and triglycerides, but E2, T, and FAI were selected in the HDL regression, explaining 3%, 2%, and less than 1%, respectively. Our regression analyses illustrate the diverging results when investigating associations between gonadal steroids and lipids with and without SHBG adjustment. Atherogenic lipid profile in males is associated with low SHBG, low T levels, and a high FAI. Males with high E2 levels may have a less atherogenic lipid profile and lower LVM. SHBG is a key hormone in the association between sex hormones and plasma lipids. We suggest that conflicting results of cross-sectional and intervention studies of sex hormones and lipids, in part, may be explained by interindividual differences or changes in SHBG. Thus, further studies on the potential role of SHBG in the development of ischemic heart disease (IHD) should be performed. Copyright 2001 by W.B. Saunders Company

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11474474     DOI: 10.1053/meta.2001.24916

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  12 in total

1.  Immunological and mass spectrometric assays of SHBG: consistent and inconsistent metabolic associations in healthy men.

Authors:  Johannes D Veldhuis; Olga P Bondar; Roy B Dyer; Sergey A Trushin; Eric W Klee; Ravinder J Singh; George G Klee
Journal:  J Clin Endocrinol Metab       Date:  2013-12-20       Impact factor: 5.958

2.  Effect of testosterone undecanoate on hematological profiles, blood lipid and viscosity and plasma testosterone level in castrated rabbits.

Authors:  Chen Zhao; Du Geon Moon; Jong Kwan Park
Journal:  Can Urol Assoc J       Date:  2013 Mar-Apr       Impact factor: 1.862

3.  Higher testosterone levels are associated with increased high-density lipoprotein cholesterol in men with cardiovascular disease: results from the Massachusetts Male Aging Study.

Authors:  Stephanie T Page; Beth A Mohr; Carol L Link; Amy B O'Donnell; William J Bremner; John B McKinlay
Journal:  Asian J Androl       Date:  2007-12-20       Impact factor: 3.285

4.  The association of endogenous sex hormones with lipoprotein subfraction profile in the Multi-Ethnic Study of Atherosclerosis.

Authors:  Dhananjay Vaidya; Adrian Dobs; Susan M Gapstur; Sherita Hill Golden; Arlene Hankinson; Kiang Liu; Pamela Ouyang
Journal:  Metabolism       Date:  2008-06       Impact factor: 8.694

5.  Biomarkers and Noncalcified Coronary Artery Plaque Progression in Older Men Treated With Testosterone.

Authors:  Kashif Shaikh; Susan S Ellenberg; Rine Nakanishi; Peter J Snyder; Juhwan Lee; Nanette K Wenger; Cora E Lewis; Ronald S Swerdloff; Peter Preston; Sajad Hamal; Alisa Stephens-Sheilds; Shalender Bhasin; Lavanya Cherukuri; Jane A Cauley; Jill P Crandall; Glenn R Cunningham; Kristine E Ensrud; Alvin M Matsumoto; Mark E Molich; Venkata M Alla; Divya Birudaraju; Negin Nezarat; Kelash Rai; Shone Almeida; Sion K Roy; Mohammad Sheikh; George Trad; Mathew J Budoff
Journal:  J Clin Endocrinol Metab       Date:  2020-07-01       Impact factor: 5.958

6.  Association of serum testosterone with lipid abnormalities in patients with angiographically proven coronary artery disease.

Authors:  Chandima Madhu Wickramatilake; Mohamed Rifdy Mohideen; Chitra Pathirana
Journal:  Indian J Endocrinol Metab       Date:  2013-11

Review 7.  Androgen actions on endothelium functions and cardiovascular diseases.

Authors:  Jing-Jing Cai; Juan Wen; Wei-Hong Jiang; Jian Lin; Yuan Hong; Yuan-Shan Zhu
Journal:  J Geriatr Cardiol       Date:  2016-02       Impact factor: 3.327

Review 8.  Role of androgens in cardiovascular pathology.

Authors:  Dimitry A Chistiakov; Veronika A Myasoedova; Alexandra A Melnichenko; Andrey V Grechko; Alexander N Orekhov
Journal:  Vasc Health Risk Manag       Date:  2018-10-15

Review 9.  The effects of endogenous and exogenous androgens on cardiovascular disease risk factors and progression.

Authors:  Panagiota Manolakou; Roxani Angelopoulou; Chris Bakoyiannis; Elias Bastounis
Journal:  Reprod Biol Endocrinol       Date:  2009-05-12       Impact factor: 5.211

10.  Basal Endogenous Steroid Hormones, Sex Hormone-Binding Globulin, Physical Fitness, and Health Risk Factors in Young Adult Men.

Authors:  Sheila S Gagnon; Bradley C Nindl; Jani P Vaara; Matti Santtila; Keijo Häkkinen; Heikki Kyröläinen
Journal:  Front Physiol       Date:  2018-07-27       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.